Abivax (ABVX) Share-based Compensation (2024 - 2026)
Abivax (ABVX) posted quarterly Share-based Compensation of $26.5 million for Q1 2026, up 436.68% year-over-year from $4.9 million in Q1 2025, and up 76.28% quarter-over-quarter from $15.0 million in Q4 2025.
Abivax (ABVX) Share-based Compensation (2024 - 2026) Analysis & Trends
Abivax's Share-based Compensation history runs 3 years deep, the most recent figure standing at $26.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 436.68% year-over-year to $26.5 million; the TTM figure through Mar 2026 stood at $62.1 million (up 201.76% YoY), while the FY2025 annual figure was $41.2 million, up 90.66% from the prior year.
- Share-based Compensation for Q1 2026 stood at $26.5 million, up from $15.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $26.5 million in Q1 2026, with the low at $4.8 million in Q4 2024.
- The 3-year median for Share-based Compensation is $6.3 million (2024), against an average of $9.9 million.
- The sharpest annual moves came in 2025 and 2026: Share-based Compensation decreased 21.11% in 2025, then surged 436.68% in 2026.
- Abivax's Share-based Compensation stood at $4.8 million in 2024, then jumped by 215.28% to $15.0 million in 2025, then surged by 76.28% to $26.5 million in 2026.
- Business Quant data shows ABVX's Share-based Compensation at $26.5 million in Q1 2026, $15.0 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 26.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.47 Mn |
| Mar 31, 2026 | 26.47 Mn |
| Dec 31, 2025 | 15.02 Mn |
| Dec 31, 2025 | 15.02 Mn |
| Sep 30, 2025 | 13.42 Mn |
| Sep 30, 2025 | 13.42 Mn |
| Jun 30, 2025 | 7.17 Mn |
| Jun 30, 2025 | 7.17 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Mar 31, 2025 | 4.93 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Dec 31, 2024 | 4.76 Mn |
| Sep 30, 2024 | 4.77 Mn |
| Sep 30, 2024 | 4.77 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Jun 30, 2024 | 6.10 Mn |
| Mar 31, 2024 | 6.25 Mn |
| Mar 31, 2024 | 6.25 Mn |